Adalimumab is effective in long-term real life clinical practice in both luminal and perianal Crohn's disease. The Madrid experience

Gastroenterologia y Hepatologia

Volumn 34, Issue 7, 2011, Pages 443-448

  Fortea Ormaechea, José Ignacio ^a   González Lama, Yago ^b   Casis, Begoña ^c   Chaparro, María ^d   López Serrano, Pilar ^e   Van Domselaar, Manuel ^f   Bermejo, Fernando ^g   Pajares, Ramón ^h   Ponferrada, Ángel ⁱ   Vera, María Isabel ^b   Martínez Montiel, Pilar ^c   Gisbert, Javier P ^d   Pérez Calle, José Luis ^e   López San Román, Antonio ^f   Abreu, Luis ^b   Menchén, Luis Alberto ^a   Marn Jimenez, Ignacio ^a  

^a HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^b HOSPITAL UNIVERSITARIO PUERTA DE HIERRO   (Spain)

^c HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^d HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

^e HOSPITAL UNIVERSITARIO FUNDACIÓN ALCORCÓN   (Spain)

^f HOSPITAL RAMÓN Y CAJAL   (Spain)

^g HOSPITAL UNIVERSITARIO DE FUENLABRADA   (Spain)

^h HOSPITAL UNIVERSITARIO INFANTA SOFÍA   (Spain)

ⁱ HOSPITAL UNIVERSITARIO INFANTA LEONOR   (Spain)

Author keywords

Adalimumab; Crohn's disease; Effectiveness; Safety

Indexed keywords

ADALIMUMAB; INFLIXIMAB;

ABDOMINAL ABSCESS; ADULT; ANAPHYLAXIS; ANUS DISEASE; ARTICLE; CHICKENPOX; CLINICAL PRACTICE; CONSCIOUSNESS DISORDER; COUGHING; CROHN DISEASE; CYTOMEGALOVIRUS INFECTION; DIARRHEA; DISEASE EXACERBATION; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG ERUPTION; DRUG INDUCED HEADACHE; DRUG RESPONSE; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; FISTULA; FOLLICULITIS; FOLLOW UP; HERPES ZOSTER; HUMAN; INJECTION SITE PAIN; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MULTICENTER STUDY; MYALGIA; PNEUMONIA; PREDICTOR VARIABLE; PSORIASIS; RETROSPECTIVE STUDY; SPAIN; TOOTH INFECTION; TREATMENT RESPONSE; TUBERCULOSIS; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION;

ABSCESS; ADULT; ANTIBODIES, MONOCLONAL, HUMANIZED; AZATHIOPRINE; COMBINED MODALITY THERAPY; CROHN DISEASE; CUTANEOUS FISTULA; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG EVALUATION; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; HOSPITALS, URBAN; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; RECTAL FISTULA; RETROSPECTIVE STUDIES; SMOKING; TUMOR NECROSIS FACTOR-ALPHA;

EID: 79961028207     PISSN: 02105705     EISSN: 15789519     Source Type: Journal    
DOI: 10.1016/j.gastrohep.2011.04.001     Document Type: Article

References (19)

1. Ricart E., García-Bosch O., Ordás I., Panés J. Are we giving biologics too late? The case for early versus late use. World J Gastroenterol 2008, 14:5523-5527.
2. Peyrin-Biroulet L., Deltenre P., de Suray N., Branche J., Sandborn W.J., Colombel J.F. Efficacy and safety of tumor necrosis factor antagonists in Crohn's disease: meta-analysis of placebo-controlled trials. Clin Gastroenterol Hepatol 2008, 6:523-644.
3. Gisbert J.P., Panés J. Loss of response and requirement of infliximab dose intensification in Crohn's disease: a review. Am J Gastroenterol 2009, 104:760-767.
4. Han P.D., Cohen R.D. Managing immunogenic responses to infliximab: treatment implications for patients with Crohn's disease. Drugs 2004, 64:1766-1767.
5. Hanauer S.B., Sandborn W.J., Rutgeerts P., Fedorak R.N., Lukas M., MacIntosh D., et al. Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial. Gastroenterology 2006, 130:323-333.
6. Colombel J.F., Sandborn W.J., Rutgeerts P., Enns R., Hanauer S.B., Panaccione R., et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology 2007, 132:52-65.
7. Sandborn W.J., Hanauer S.B., Rutgeerts P., Fedorak R.N., Lukas M., MacIntosh D.G., et al. Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial. Gut 2007, 56:1232-1239.
8. Sandborn W.J., Rutgeerts P., Enns R., Hanauer S.B., Colombel J.F., Panaccione R., et al. Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trial. Ann Intern Med 2007, 146:829-838.
9. Feagan B.G., Panaccione R., Sandborn W.J., D'Haens G.R., Schreiber S., Rutgeerts P.J., et al. Effects of adalimumab therapy on incidence of hospitalization and surgery in Crohn's disease: results from the CHARM study. Gastroenterology 2008, 135:1493-1499.
10. Colombel J.F., Schwartz D.A., Sandborn W.J., Kamm M.A., D'Haens G., Rutgeerts P., et al. Adalimumab for the treatment of fistulas in patients with Crohn's disease. Gut 2009, 58:940-948.
11. Hinojosa J., Gomollón F., García S., Bastida G., Cabriada J.L., Saro C., et al. Efficacy and safety of short-term adalimumab treatment in patients with active Crohn's disease who lost response or showed intolerance to infliximab: a prospective, open-label, multicentre trial. Aliment Pharmacol Ther 2007, 25:409-418.
12. Peyrin-Biroulet L., Laclotte C., Bigard M.A. Adalimumab maintenance therapy for Crohn's disease with intolerance or lost response to infliximab: an open-label study. Aliment Pharmacol Ther 2007, 25:675-680.
13. Papadakis K.A., Shaye O.A., Vasiliauskas E.A., Ippoliti A., Dubinsky M.C., Birt J., et al. Safety and efficacy of adalimumab (D2E7) in Crohn's disease patients with an attenuated response to infliximab. Am J Gastroenterol 2005, 100:75-79.
14. Youdim A., Vasiliauskas E.A., Targan S.R., Papadakis K.A., Ippoliti A., Dubinsky M.C., et al. A pilot study of adalimumab in infliximab-allergic patients. Inflamm Bowel Dis 2004, 10:333-338.
15. Sandborn W.J., Hanauer S., Loftus E.V., Tremaine W.J., Kane S., Cohen R., et al. An open-label study of the human anti-TNF monoclonal antibody adalimumab in subjects with prior loss of response or intolerance to infliximab for Crohn's disease. Am J Gastroenterol 2004, 99:1984-1989.
16. López Palacios N., Mendoza J.L., Taxonera C., Lana R., Fuentes Ferrer M., Díaz-Rubio M. Adalimumab induction and maintenance therapy for Crohn's disease. An open-label study. Rev Esp Enferm Dig 2008, 100:676-681.
17. Ho G.T., Smith L., Aitken S., Lee H.M., Ting T., Fennell J., et al. The use of adalimumab in the management of refractory Crohn's disease. Aliment Pharmacol Ther 2008, 27:308-315.
18. Ho G.T., Mowat A., Potts L., Cahill A., Mowat C., Lees C.W., et al. Efficacy and complications of adalimumab treatment for medically-refractory Crohn's disease: analysis of nationwide experience in Scotland (2004-2008). Aliment Pharmacol Ther 2009, 29:527-534.
19. Swaminath A., Ullman T., Rosen M., Mayer L., Lichtiger S., Abreu M.T. Early clinical experience with adalimumab in treatment of inflammatory bowel disease with infliximab-treated and naïve patients. Aliment Pharmacol Ther 2009, 29:273-278.